Bill > HB1734

This bill establishes a committee composed of members from the New Hampshire Senate and House of Representatives to study the feasibility and oversight of experimental treatment centers within the state. The committee's duties include determining the necessary oversight mechanisms for the Department of Health and Human Services, the Bureau of Consumer Protection, and the Office of Professional Licensure and Certification, and gathering testimony from these agencies, existing experimental treatment centers, and experts in drug approval processes and manufacturing practices. The committee will also research similar centers in other states, examining their benefits, consequences, patient outcomes, and costs, as well as the challenges of oversight. The committee will elect a chairperson, requires four members for a quorum, and must report its findings and legislative recommendations by November 1, 2026. The bill also includes a fiscal note indicating potential significant expenditures for the Department of Health and Human Services to establish new units, hire staff, and contract consultants to manage the regulation of these centers, with estimated first-year costs around $2.5 million and ongoing costs of $1 million or more, though revenue from authorization fees is indeterminable.